Open Access

A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children

Maj Friberg Birkedal

Maj Friberg Birkedal

Haemophilia Treatment Centre, RigshospitaletCopenhagen, Denmark
Orcid profile
Search for this author on
Sciendo|Google Scholar
Birkedal, Maj Friberg
  
Dec 31, 2024
A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Clinical Practice
Published Online: Dec 31, 2024
Page range: 129 - 135
DOI: https://doi.org/10.2478/jhp-2024-0019
Keywords
© 2024 Maj Friberg Birkedal, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
A retrospective study finds the Neria™ Guard device to be effective in reducing pain and distress among children receiving treatment with emicizumab but recognises the need for further research and a validated, stability-tested solution
A retrospective study finds the Neria™ Guard device to be effective in reducing pain and distress among children receiving treatment with emicizumab but recognises the need for further research and a validated, stability-tested solution

Figure 1.

Photographs showing use of the Neria™ Guard device, which enables slow infusion during subcutaneous drug delivery
Photographs showing use of the Neria™ Guard device, which enables slow infusion during subcutaneous drug delivery

Figure 2.

Diagram showing component parts of the Neria™ Guard device
Diagram showing component parts of the Neria™ Guard device

j_jhp-2024-0019_utab_001

COMPONENT NUMBER COMPONENT MATERIAL
1 Cylinder Polypropylene (PP)
2 Fluid part base Polypropylene (PP)
3 Septum (injection port) Silicone, Elastosil
4 Bushing Polycarbonate (PC)
5 Introducer needle Stainless steel, AiSi 304
6 Releaser Polyoxymethylene copolymer (POM)
7 Base Co-polyester
8 Adhesive patch Polyester with polyacrylate adhesive
9 Connector in grey colour Methyl methacrylate acrylonitrile butadiene styrene (MABS), Terlux 2802 HD, transparent, grey
10 Cover Polypropylene (PP), grey
11 Release button Polypropylene (PP), red
12 Luer Methyl methacrylate acrylonitrile butadiene styrene (MABS), Terlux 2802 HD, transparent
13 Connector needle Stainless steel, AiSi 304
14 Fixation tape Bandarole, Flexpeel
15 Protective cap for connector Polypropylene (PP)
16 Blister Amorphous polyethylene terephthalate/polyethylene (APET/PE)
17 Blister lid Medical grade paper
18 Extruder tube:Inner tubeOuter tube Polyethylene (PE)Polyurethane (PUR)
19 Reinforcement liner(part of adhesive patch ID #8) Polyethylene terephthalate (PET) and acrylic adhesive
20 Neeedle hub Polyoxymethylene (POM)
21 Soft catheter Polytetrafluoroethylene (PTFE)
22 Piston Polyoxymethylene copolymer (POM)
23 Retraction spring Stainless steel spring wire (AiSi 302)
24 Insertion spring Stainless steel spring wire (AiSi 302)
25 Base lock Polypropylene (PP)
26 N/A UV glue
27 N/A Silicone oil

Serum emicizumab in the study population after initiation of Neria™ Guard

PATIENT NO. TREATMENT INTERVAL DAYS FROM LAST INJECTION TO BLOOD SAMPLE DAYS FROM INITIATION OF NERIA™ GUARD TO BLOOD SAMPLE MEASURED EMICIZUMAB PLASMA LEVELS
1 Every 14 days 8 36 53 μg/L
2 Every 14 days 2 92 62 μg/L
3 Every 14 days 8 54 33 μg/L
4 1 × week 5 61 71 μg/L
5 1 × week 5 61 41 μg/L
6 Every 20 days No data available 56 52 μg/L
7 Every 14 days 1 57 57 μg/L
8 Every 14 days 12 72 65 μg/L
9 Every 14 days 12 72 62 μg/L
10 Every 14 days 9 37 48 μg/L
11 1 × week 0 35 49 μg/L
Language:
English
Publication timeframe:
1 times per year
Journal Subjects:
Medicine, Basic Medical Science, Basic Medical Science, other, Clinical Medicine, Clinical Medicine, other, Pharmacy, Pharmacology
Journal RSS Feed